TILT Biotherapeutics, a Finnish company developing cancer immunotherapies, reported the final close of its €22m (US$23.8m) round, which was led by Finland’s Lifeline Ventures, an early-stage venture capital firm.
BioInvent, a Swedish biotech focused on the discovery and development of immuno-regulatory antibodies for oncology, reports that it has been contracted as manufacturer of Cantargia’s antibody CAN10.
Researchers from MIT have devised a way for T cells to be engineered to carry nanoparticle ‘backpacks’ that can deliver the payload only when interacting with the target tumour cells.
